Solo Containment’s Martyn Ryder has been observing environmental monitoring systems from as early as 1989.

The growth of lyophilization and its complicated processes has challenged manufacturers to maintain safety for operators working with highly potent ingredients, which has created a demand to assure product quality and protection from contamination.

Myriad considerations, spanning the full complement of pharmaceutical manufacturing stakeholders, influence the containment solution decision-making process in pharmaceutical manufacturing.

As the potency of drug substances continues to increase, so does the requirement for containment solutions that reduce cross-contamination risks without breaking the bank.